| Literature DB >> 22731103 |
Pramod Kumar Mishra1, Judy M Teale.
Abstract
BACKGROUND: Central nervous system (CNS) barriers play a pivotal role in the protection and homeostasis of the CNS by enabling the exchange of metabolites while restricting the entry of xenobiotics, blood cells and blood-borne macromolecules. While the blood-brain barrier and blood-cerebrospinal fluid barrier (CSF) control the interface between the blood and CNS, the ependyma acts as a barrier between the CSF and parenchyma, and regulates hydrocephalic pressure and metabolic toxicity. Neurocysticercosis (NCC) is an infection of the CNS caused by the metacestode (larva) of Taenia solium and a major cause of acquired epilepsy worldwide. The common clinical manifestations of NCC are seizures, hydrocephalus and symptoms due to increased intracranial pressure. The majority of the associated pathogenesis is attributed to the immune response against the parasite. The properties of the CNS barriers, including the ependyma, are affected during infection, resulting in disrupted homeostasis and infiltration of leukocytes, which correlates with the pathology and disease symptoms of NCC patients.Entities:
Mesh:
Substances:
Year: 2012 PMID: 22731103 PMCID: PMC3527296 DOI: 10.1186/1742-2094-9-141
Source DB: PubMed Journal: J Neuroinflammation ISSN: 1742-2094 Impact factor: 8.322
Figure 1Immunofluorescence labeling of ependymal cells. (A) Immunofluorescence labeling of cryostat sections from snap frozen brain tissue for ependymal cells (e) using anti- β catenin antibody followed by serial dehydration (B). Same section after subjected to LCM-mediated ependymal cells isolation.
Figure 2Differentially expressed probe set in ependymal cells. Hierarchical cluster analysis of the differentially expressed probe sets by two or more fold; 563 probe sets were significantly affected, (red = upregulated, green = downregulated). Mock A, B and C represent individual biological samples from infected animals (n = 3). Three-week p.i. A, B and C represent individual biological samples from M. corti-infected mice (n = 3).
List of the most up- and downregulated (−) genes in ependymal cells from -infected brain in comparison to mock-infected brain samples
| ARG1 | 142.1 | Arginase activity | Arginine and proline metabolism; urea cycle and metabolism of amino groups |
| CD74 | 126.8 | MHC class II protein binding | Antigen processing and presentation of exogenous peptide antigen via MHC class II |
| CCL8 | 83.18 | Chemokine activity; heparin binding | Cell-cell signaling; chemotaxis |
| SAA1 | 77.66 | G-protein coupled receptor binding | Acute-phase response; chemotaxis |
| PSMB9 | 74.76 | Peptidase activity | Antigen processing and presentation; aprotein polyubiquitination |
| HLA-C | 53.43 | Beta-2-microglobulin binding; MHC class I receptor activity | Antigen processing and presentation of peptide antigen via MHC class I |
| SRGN | 53.19 | Collagen binding; protein binding | Apoptotic process; biomineral tissue development; blood coagulation; maintenance of granzyme B location in T cell secretory granule |
| HLA-E | 39.98 | MHC class I receptor activity | Antigen processing and presentation of peptide antigen via MHC class I |
| HLA-B | 36.35 | MHC class I receptor activity | Antigen processing and presentation of peptide antigen via MHC class I |
| C3AR1 | 33.81 | Complement component C3a receptor activity; G-protein coupled receptor activity; | Chemotaxis; complement receptor-mediated signaling pathway |
| ST18 | −23.92 | DNA binding | Regulation of transcription |
| ONECUT2 | −20.08 | Sequence-specific DNA binding transcription factor activity | Cell fate commitment; cilium assembly; epithelial cell development |
| CEP76 | −17.01 | Protein binding | Regulation of centriole replication |
| TNNT3 | −11.99 | Actin binding; calcium- dependent ATPase activity | Muscle contraction; muscle filament sliding; regulation of ATPase activity |
| AZI2 | −6.99 | TBK1/IKKi-binding | I-kappaB kinase/NF-kappaB cascade |
| METTL2B | −6.85 | Methyltransferase activity; transferase activity | Methylation |
| PCF11 | −6.8 | RNA 3'-end processing | Termination of RNA polymerase II transcription |
| C20ORF24 | −6.67 | ND | ND |
| ACBD3 | −6.37 | Fatty-acyl-CoA binding | Lipid biosynthetic process; steroid biosynthetic process; transport |
| SFRS8 | −5.65 | RNA binding | Negative regulation of nuclear mRNA splicing, regulation of transcription |
ND, not determined.
Top biological functions associated with genes differentially expressed in ependymal cells from NCC brain
| | | |
| Inflammatory response | 9.03E-19 - 1.61E-03 | 109 |
| Immunological disease | 2.87E-13 - 1.37E-03 | 111 |
| Inflammatory disease | 1.25E-11 - 9.66E-04 | 127 |
| Respiratory disease | 1.84E-11 - 9.10E-04 | 51 |
| Connective tissue disorders | 2.15E-10 - 7.88E-04 | 90 |
| Cellular development | 4.49E-14 - 1.61E-03 | 97 |
| Cellular movement | 5.98E-12 - 1.32E-03 | 79 |
| Cellular growth and proliferation | 2.37E-11 - 1.61E-03 | 122 |
| Cell-to-cell signaling and interaction | 1.36E-10 - 1.61E-03 | 82 |
| Cell death | 2.87E-09 - 1.58E-03 | 113 |
| Hematological system development and function | 1.29E-11 - 1.61E-03 | 102 |
| Immune cell trafficking | 1.29E-11 - 1.61E-03 | 73 |
| Tissue morphology | 9.56E-11 - 1.45E-03 | 53 |
| Hematopoiesis | 4.10E-10 - 1.56E-03 | 60 |
| Cell-mediated immune response | 3.05E-08 - 1.27E-03 | 47 |
Figure 3Schematic representation of the most significant networks predicted by IPA. (A) Shape and relation legends. (B) Antigen presentation, inflammatory response, immunological disease. (C) Small molecule biochemistry, carbohydrate metabolism, molecular transport. (D) Antimicrobial response, inflammatory response, cell-to-cell signaling interaction. Red shape represents upregulated, green shape represents downregulated, and white boxes represent genes not present in the data sets but relevant to biological pathways and incorporated to generate networks.
Figure 4Schematic representation of the most significantly affected pathway: “Antigen presentation pathway.” (Red indicates upregulated genes in the ependymal cells from infected brain in comparison to ependymal cells from mock-infected brain samples.).
Verification of infection-induced gene expression in the ependyma by real-time PCR
| ΔΔ | |||||
|---|---|---|---|---|---|
| ARG1 | NM_007482 | 142.1 | 20.67 | 0.44 | <0.001 |
| MRC1 | NM_008625 | 7.893 | 4.71 | 0.30 | 0.001 |
| B2M | NM_009735 | 19.11 | 4.49 | 0.45 | <0.01 |
| C3 | NM_009778 | 14.46 | 4.50 | 0.26 | <0.001 |
| CCL2 | NM_011333 | 3.205 | 14.10 | 0.65 | <0.001 |
| CCL12 | NM_011331 | 18.84 | 7.58 | 0.82 | <0.01 |
| CXCL10 | NM_021274 | 2.929 | 10.68 | 2.95 | <0.05 |
| CXCL11 | NM_019494 | 21.73 | 10.13 | 1.60 | <0.01 |
| FN1 | NM_010233 | 13.49 | 5.67 | 0.78 | <0.01 |
| STAT1 | NM_009283 | 6.53 | 4.07 | 0.45 | <0.01 |
| H2-Ea | NM_010381 | 16.41 | 10.54 | 1.20 | <0.01 |
Figure 5Schematic representation of the most significantly affected pathway: “Antigen presentation pathway.(a) MHC II expression in the ependyma, A1. Mock (IF + DIC, 20×), A2. Infected (IF + DIC, 20×). Magnified images (63×) showing ependyma during NCC without DIC (A3) and with DIC (A4). (b) Chemokine CCL12 (B1-B4) and CCL5 (B5-B6) expression in ependyma, B1. Mock (IF + DIC, 20×), B2. Infected (IF + DIC, 20×). Magnified images showing CCL12 expression near parasite (B3) and cellular distribution of CCL12 (B4, 63×), CCL5 expression in mock (B5, IF, 40×) and infected (B6, IF, 40×). (e = ependyma, CP = choroid plexus, P = parasite).